Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome

P. Artur Plett, Carol H. Sampson, Hui Lin Chua, Mandar Joshi, Catherine Booth, Alec Gough, Cynthia S. Johnson, Barry Katz, Ann M. Farese, Jeffrey Parker, Thomas J. MacVittie, Christie Orschell

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The authors have developed a murine model of the Hematopoietic Syndrome of the Acute Radiation Syndrome (H-ARS) for efficacy testing of medical countermeasures (MCM) against radiation according to the FDA Animal Rule. Ten- to 12-wk-old male and female C57BL/6 mice were exposed to the LD50/30-LD70/30 dose of total body irradiation (TBI, 137Cs, 0.62-0.67 Gy min -1) in the morning hours when mice were determined to be most radiosensitive, and they were assessed for 30-d survival and mean survival time (MST). Antibiotics were delivered in drinking water on days 4-30 post-TBI at a concentration based on the amount of water that lethally-irradiated mice were found to consume. The fluoroquinolones, ciprofloxacin and levofloxacin, as well as the tetracycline doxycycline, and aminoglycoside neomycin, all significantly increased MST of decedent mice, while ciprofloxacin (p = 0.061) and doxycycline + neomycin (p = 0.005) showed at least some efficacy to increase 30-d survival. Blood sampling (30 μL/mouse every fifth day) was found to negatively impact 30-d survival. Histopathology of tissues harvested from nonmoribund mice showed expected effects of lethal irradiation, while moribund mice were largely septicemic with a preponderance of enteric organisms. Kinetics of loss and recovery of peripheral blood cells in untreated mice and those treated with two MCM, granulocyte-colony stimulating factor and Amifostine further characterized and validated this model for use in screening studies and pivotal efficacy studies of candidate MCM for licensure to treat irradiated individuals suffering from H-ARS.

Original languageEnglish
Pages (from-to)343-355
Number of pages13
JournalHealth Physics
Volume103
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Acute Radiation Syndrome
Neomycin
Doxycycline
Ciprofloxacin
Medical Licensure
Survival Rate
Amifostine
Levofloxacin
Whole-Body Irradiation
Lethal Dose 50
Fluoroquinolones
Aminoglycosides
Granulocyte Colony-Stimulating Factor
Tetracycline
Inbred C57BL Mouse
Drinking Water
Blood Cells
Radiation
Anti-Bacterial Agents
Water

Keywords

  • blood mice
  • Dose assessment
  • modeling
  • radiation dose

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis
  • Epidemiology

Cite this

Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. / Plett, P. Artur; Sampson, Carol H.; Chua, Hui Lin; Joshi, Mandar; Booth, Catherine; Gough, Alec; Johnson, Cynthia S.; Katz, Barry; Farese, Ann M.; Parker, Jeffrey; MacVittie, Thomas J.; Orschell, Christie.

In: Health Physics, Vol. 103, No. 4, 10.2012, p. 343-355.

Research output: Contribution to journalArticle

Plett, PA, Sampson, CH, Chua, HL, Joshi, M, Booth, C, Gough, A, Johnson, CS, Katz, B, Farese, AM, Parker, J, MacVittie, TJ & Orschell, C 2012, 'Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome', Health Physics, vol. 103, no. 4, pp. 343-355. https://doi.org/10.1097/HP.0b013e3182667309
Plett, P. Artur ; Sampson, Carol H. ; Chua, Hui Lin ; Joshi, Mandar ; Booth, Catherine ; Gough, Alec ; Johnson, Cynthia S. ; Katz, Barry ; Farese, Ann M. ; Parker, Jeffrey ; MacVittie, Thomas J. ; Orschell, Christie. / Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. In: Health Physics. 2012 ; Vol. 103, No. 4. pp. 343-355.
@article{0fd91dd3b3704db1bbedf7a33a52b30d,
title = "Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome",
abstract = "The authors have developed a murine model of the Hematopoietic Syndrome of the Acute Radiation Syndrome (H-ARS) for efficacy testing of medical countermeasures (MCM) against radiation according to the FDA Animal Rule. Ten- to 12-wk-old male and female C57BL/6 mice were exposed to the LD50/30-LD70/30 dose of total body irradiation (TBI, 137Cs, 0.62-0.67 Gy min -1) in the morning hours when mice were determined to be most radiosensitive, and they were assessed for 30-d survival and mean survival time (MST). Antibiotics were delivered in drinking water on days 4-30 post-TBI at a concentration based on the amount of water that lethally-irradiated mice were found to consume. The fluoroquinolones, ciprofloxacin and levofloxacin, as well as the tetracycline doxycycline, and aminoglycoside neomycin, all significantly increased MST of decedent mice, while ciprofloxacin (p = 0.061) and doxycycline + neomycin (p = 0.005) showed at least some efficacy to increase 30-d survival. Blood sampling (30 μL/mouse every fifth day) was found to negatively impact 30-d survival. Histopathology of tissues harvested from nonmoribund mice showed expected effects of lethal irradiation, while moribund mice were largely septicemic with a preponderance of enteric organisms. Kinetics of loss and recovery of peripheral blood cells in untreated mice and those treated with two MCM, granulocyte-colony stimulating factor and Amifostine further characterized and validated this model for use in screening studies and pivotal efficacy studies of candidate MCM for licensure to treat irradiated individuals suffering from H-ARS.",
keywords = "blood mice, Dose assessment, modeling, radiation dose",
author = "Plett, {P. Artur} and Sampson, {Carol H.} and Chua, {Hui Lin} and Mandar Joshi and Catherine Booth and Alec Gough and Johnson, {Cynthia S.} and Barry Katz and Farese, {Ann M.} and Jeffrey Parker and MacVittie, {Thomas J.} and Christie Orschell",
year = "2012",
month = "10",
doi = "10.1097/HP.0b013e3182667309",
language = "English",
volume = "103",
pages = "343--355",
journal = "Health Physics",
issn = "0017-9078",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome

AU - Plett, P. Artur

AU - Sampson, Carol H.

AU - Chua, Hui Lin

AU - Joshi, Mandar

AU - Booth, Catherine

AU - Gough, Alec

AU - Johnson, Cynthia S.

AU - Katz, Barry

AU - Farese, Ann M.

AU - Parker, Jeffrey

AU - MacVittie, Thomas J.

AU - Orschell, Christie

PY - 2012/10

Y1 - 2012/10

N2 - The authors have developed a murine model of the Hematopoietic Syndrome of the Acute Radiation Syndrome (H-ARS) for efficacy testing of medical countermeasures (MCM) against radiation according to the FDA Animal Rule. Ten- to 12-wk-old male and female C57BL/6 mice were exposed to the LD50/30-LD70/30 dose of total body irradiation (TBI, 137Cs, 0.62-0.67 Gy min -1) in the morning hours when mice were determined to be most radiosensitive, and they were assessed for 30-d survival and mean survival time (MST). Antibiotics were delivered in drinking water on days 4-30 post-TBI at a concentration based on the amount of water that lethally-irradiated mice were found to consume. The fluoroquinolones, ciprofloxacin and levofloxacin, as well as the tetracycline doxycycline, and aminoglycoside neomycin, all significantly increased MST of decedent mice, while ciprofloxacin (p = 0.061) and doxycycline + neomycin (p = 0.005) showed at least some efficacy to increase 30-d survival. Blood sampling (30 μL/mouse every fifth day) was found to negatively impact 30-d survival. Histopathology of tissues harvested from nonmoribund mice showed expected effects of lethal irradiation, while moribund mice were largely septicemic with a preponderance of enteric organisms. Kinetics of loss and recovery of peripheral blood cells in untreated mice and those treated with two MCM, granulocyte-colony stimulating factor and Amifostine further characterized and validated this model for use in screening studies and pivotal efficacy studies of candidate MCM for licensure to treat irradiated individuals suffering from H-ARS.

AB - The authors have developed a murine model of the Hematopoietic Syndrome of the Acute Radiation Syndrome (H-ARS) for efficacy testing of medical countermeasures (MCM) against radiation according to the FDA Animal Rule. Ten- to 12-wk-old male and female C57BL/6 mice were exposed to the LD50/30-LD70/30 dose of total body irradiation (TBI, 137Cs, 0.62-0.67 Gy min -1) in the morning hours when mice were determined to be most radiosensitive, and they were assessed for 30-d survival and mean survival time (MST). Antibiotics were delivered in drinking water on days 4-30 post-TBI at a concentration based on the amount of water that lethally-irradiated mice were found to consume. The fluoroquinolones, ciprofloxacin and levofloxacin, as well as the tetracycline doxycycline, and aminoglycoside neomycin, all significantly increased MST of decedent mice, while ciprofloxacin (p = 0.061) and doxycycline + neomycin (p = 0.005) showed at least some efficacy to increase 30-d survival. Blood sampling (30 μL/mouse every fifth day) was found to negatively impact 30-d survival. Histopathology of tissues harvested from nonmoribund mice showed expected effects of lethal irradiation, while moribund mice were largely septicemic with a preponderance of enteric organisms. Kinetics of loss and recovery of peripheral blood cells in untreated mice and those treated with two MCM, granulocyte-colony stimulating factor and Amifostine further characterized and validated this model for use in screening studies and pivotal efficacy studies of candidate MCM for licensure to treat irradiated individuals suffering from H-ARS.

KW - blood mice

KW - Dose assessment

KW - modeling

KW - radiation dose

UR - http://www.scopus.com/inward/record.url?scp=84866030616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866030616&partnerID=8YFLogxK

U2 - 10.1097/HP.0b013e3182667309

DO - 10.1097/HP.0b013e3182667309

M3 - Article

C2 - 22929467

AN - SCOPUS:84866030616

VL - 103

SP - 343

EP - 355

JO - Health Physics

JF - Health Physics

SN - 0017-9078

IS - 4

ER -